CY1122568T1 - MANAGEMENT OF OSTEOPOROSIS WITH HMW PEG - Google Patents

MANAGEMENT OF OSTEOPOROSIS WITH HMW PEG

Info

Publication number
CY1122568T1
CY1122568T1 CY20191100930T CY191100930T CY1122568T1 CY 1122568 T1 CY1122568 T1 CY 1122568T1 CY 20191100930 T CY20191100930 T CY 20191100930T CY 191100930 T CY191100930 T CY 191100930T CY 1122568 T1 CY1122568 T1 CY 1122568T1
Authority
CY
Cyprus
Prior art keywords
osteoporosis
management
hmw peg
administration
animal
Prior art date
Application number
CY20191100930T
Other languages
Greek (el)
Inventor
Rifat Pamukcu
Laura Rae MCCABE
Original Assignee
Midway Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Midway Pharmaceuticals, Inc. filed Critical Midway Pharmaceuticals, Inc.
Publication of CY1122568T1 publication Critical patent/CY1122568T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με τη χορήγηση συνθέσεων που περιέχουν πολυαιθυλενογλυκόλη, για τη βελτίωση της γενικής γαστρεντερικής υγείας ενός ζώου αυξάνοντας την αναπτυξιακή απόδοση και θεραπεύοντας την οστεοπενία, την οστεοπόρωση και άλλες οστικές διαταραχές.The present invention relates to the administration of compositions containing polyethylene glycol to improve the general gastrointestinal health of an animal by increasing growth performance and treating osteopenia, osteoporosis and other bone disorders.

CY20191100930T 2013-03-15 2019-09-05 MANAGEMENT OF OSTEOPOROSIS WITH HMW PEG CY1122568T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361798481P 2013-03-15 2013-03-15
PCT/US2014/028832 WO2014144425A1 (en) 2013-03-15 2014-03-14 Managing osteoporosis with hmw peg

Publications (1)

Publication Number Publication Date
CY1122568T1 true CY1122568T1 (en) 2021-01-27

Family

ID=51537706

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100930T CY1122568T1 (en) 2013-03-15 2019-09-05 MANAGEMENT OF OSTEOPOROSIS WITH HMW PEG

Country Status (11)

Country Link
US (2) US10045949B2 (en)
EP (1) EP2968159B1 (en)
JP (3) JP6275239B2 (en)
AU (2) AU2014229082C1 (en)
CY (1) CY1122568T1 (en)
DK (1) DK2968159T3 (en)
ES (1) ES2744828T3 (en)
HU (1) HUE045032T2 (en)
PL (1) PL2968159T3 (en)
PT (1) PT2968159T (en)
WO (1) WO2014144425A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111419823B (en) * 2020-04-30 2022-03-29 上海公谊药业有限公司 Tiamulin fumarate enteric-coated pellet as well as preparation method and application thereof
NL1044084B1 (en) 2021-07-05 2023-01-11 Evers Agro B V MANURE INJECTOR

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10338646A (en) * 1996-08-26 1998-12-22 Takeda Chem Ind Ltd Pharmaceutical composition for stimulating formation of bone
JP5271475B2 (en) * 2002-11-26 2013-08-21 ザ ユニヴァーシティー オヴ シカゴ Materials and methods for prevention and treatment of microbial mediated epithelial diseases
JPWO2004105825A1 (en) 2003-01-10 2006-07-20 多木化学株式会社 Biomaterial for bone formation, formulation for injection containing the material, kit for preparing the material, and bone formation method using them
MXPA06012070A (en) * 2004-04-20 2007-04-24 Univ Chicago Therapeutic delivery system comprising a high molecular weight peg-like compound.
US8840933B2 (en) * 2006-05-03 2014-09-23 Warsaw Orthopedic, Inc. Method of treating neuronal injury by administering magnesium chloride and PEG
US9675696B2 (en) * 2006-11-14 2017-06-13 Warsaw Orthopedic, Inc. Method and use for increasing efficacy of anti-adhesive compositions in controlling inflammation and pain
US8153112B2 (en) * 2007-08-03 2012-04-10 Warsaw Orthopedic, Inc. Compositions and methods for treating cavity conditions
BRPI1009852A2 (en) 2009-03-23 2015-08-25 Univ Chicago Use of a high molecular weight polyethylene glycol compound
EP2468265A3 (en) * 2010-12-04 2013-01-02 DEEF Pharmaceutical Industries Co. Homogeneous preparations containing vitamin D

Also Published As

Publication number Publication date
EP2968159B1 (en) 2019-06-12
JP2016513738A (en) 2016-05-16
JP2017082009A (en) 2017-05-18
US20190015353A1 (en) 2019-01-17
AU2014229082A1 (en) 2015-11-05
US10045949B2 (en) 2018-08-14
ES2744828T3 (en) 2020-02-26
JP6619849B2 (en) 2019-12-11
AU2018250501A1 (en) 2018-11-15
DK2968159T3 (en) 2019-08-12
HUE045032T2 (en) 2019-12-30
AU2018250501B2 (en) 2020-06-25
AU2014229082B2 (en) 2018-07-19
EP2968159A4 (en) 2016-09-28
JP2018162328A (en) 2018-10-18
PL2968159T3 (en) 2019-11-29
US20160000730A1 (en) 2016-01-07
EP2968159A1 (en) 2016-01-20
JP6275239B2 (en) 2018-02-07
PT2968159T (en) 2019-10-01
WO2014144425A1 (en) 2014-09-18
AU2014229082C1 (en) 2019-01-17

Similar Documents

Publication Publication Date Title
CY1124729T1 (en) PHARMACEUTICAL FORMS OF ENZALUTHAMIDE
CY1122329T1 (en) ANTI-SIGLEC-8 ANTIBODIES AND METHODS OF USING THEM
CY1123476T1 (en) NUCLEAR TRANSPORT MODIFIERS AND THEIR USES
CY1122786T1 (en) DOSAGE FORMS FOR Echinocandin Class Compounds
CY1120529T1 (en) FUMARS PRODUCTS AND THEIR USE IN EDUCATION OF VARIOUS DISEASES
CY1122730T1 (en) 1,2,4-TRIAZOLES AS NUCLEAR TRANSPORT MODULATORS AND THEIR USES
CY1121928T1 (en) PHARMACEUTICAL COMPOSITION OF S-KETAMINE HYDROCHLORIDE
CY1122796T1 (en) IMPROVED PHARMACEUTICAL FORMS OF ADENOS
BR112017010173A2 (en) fabric treatment composition
CY1119110T1 (en) REGULATORS P2X7
CY1123953T1 (en) DELAYED RELEASE COMPOSITIONS OF LINACLOTIDE
CY1121736T1 (en) ARAMCHOL SALTS
CY1119489T1 (en) Substituted Pepper-Ethyl-Pyrimidine as Suspension of Ghrelin O-Acyl Transfer
EA201691988A1 (en) DERIVATIVES OF BORONIC ACID AND THEIR THERAPEUTIC APPLICATION
CR20160419A (en) NEW BICYCLE COMPOUNDS
EA201692301A1 (en) DERIVATIVES OF BORONIC ACID AND THEIR THERAPEUTIC APPLICATION
EA201691259A1 (en) REGULATORS Nrf2
UY34763A (en) INHIBITORS OF THE PLAQUETARY AGGREGATION
BR112017010177A2 (en) fabric treatment composition
EA201490806A1 (en) COMBINED COMPOSITION OF TWO ANTI-VIRUS COMPOUNDS
EA201591004A1 (en) DERIVATIVES OF BORONIC ACID AND THEIR THERAPEUTIC APPLICATION
EA201790273A1 (en) FLAGELLIN COMPOSITIONS AND THEIR APPLICATION
EA201591137A1 (en) MK2 INHIBITORS AND THEIR APPLICATIONS
EA201591728A1 (en) HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR APPLICATION
EA201792465A1 (en) CONNECTIONS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY